Cargando…
Injectable Lipid-Based Depot Formulations: Where Do We Stand?
The remarkable number of new molecular entities approved per year as parenteral drugs, such as biologics and complex active pharmaceutical ingredients, calls for innovative and tunable drug delivery systems. Besides making these classes of drugs available in the body, injectable depot formulations o...
Autores principales: | Rahnfeld, Lisa, Luciani, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356974/ https://www.ncbi.nlm.nih.gov/pubmed/32575406 http://dx.doi.org/10.3390/pharmaceutics12060567 |
Ejemplares similares
Ejemplares similares
-
ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011) -
Where Do We Stand?
Publicado: (1891) -
Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012) -
Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013) -
Schistosomiasis vaccines: where do we stand?
por: Tebeje, Biniam Mathewos, et al.
Publicado: (2016)